JULIE MARHEFKA: Open Payments
NPI 1699077123 · OCEANSIDE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$962 in 42 payments from 10 companies in 2025. Trend: 2023 $719 · 2024 $639 · 2025 $962
Food & beverage: $962
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 9 | $217 |
| Vanda Pharmaceuticals Inc. | 6 | $178 |
| Neurocrine BioSciences, Inc. | 4 | $122 |
| Teva Pharmaceuticals USA, Inc. | 6 | $111 |
| ABBVIE INC. | 4 | $91 |
| Otsuka America Pharmaceutical, Inc. | 4 | $81 |
| Alkermes, Inc. | 3 | $62 |
| Janssen Pharmaceuticals, Inc | 2 | $40 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $31 |
| Lundbeck LLC | 2 | $30 |
Products named: COBENFY, HETLIOZ, INGREZZA, VRAYLAR, AUSTEDO XR, ARISTADA, FANAPT, REXULTI.
Industry payments across CA — which companies pay providers there.
